Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
37250503
Public Release Type:
Journal
Publication Year: 2023
Affiliation: Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL.; RTI Health Solutions, Research Triangle Park, NC.; RTI Health Solutions, Research Triangle Park, NC.; RTI Health Solutions, Research Triangle Park, NC.; Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, MD.; Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, MD.; Otsuka Pharmaceutical Development & Commercialization, Inc, Rockville, MD.
DOI:
https://doi.org/10.1016/j.xkme.2023.100639
Authors:
Chebib Fouad T, Zhou Xiaolei, Garbinsky Diana, Davenport Eric, Nunna Sasikiran, Oberdhan Dorothee, Fernandes Ancilla
Request IDs:
21540
Studies:
The HALT Progression of Polycystic Kidney Disease (HALT-PKD)
Tolvaptan is indicated for treatment of patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. Participants aged 56-65 years constituted a small proportion of the Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trial population. We assessed effects of tolvaptan on estimated glomerular filtration rate (eGFR) decline in participants aged >55 years.
